# Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

> **NCT01221506** · EARLY_PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 20 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Pazopanib
- **DEVICE:** DCE-MRI and Quantitative Doppler Ultrasound

## Key facts

- **NCT ID:** NCT01221506
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-06
- **Final completion:** 2019-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221506, "Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*